News
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...
Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...
Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback